←
ESMO Open2,730 posts
ESMO Open avatar✓

ESMO Open ✓

@ESMO_Open

The Open Access journal of @myESMO dedicated to oncology research

◷ Joined September 2015▧ 476 Photos and videos
Paolo Tarantino avatar
⟳ ESMO Open retweeted
Paolo Tarantino@PTarantinoMD·Oct 26

Primary results from BRIDGET ph2 trial presented by @drsarahsam and published in @ESMO_Open. Adding tucatinib to HP after an isolated intracranial PD led to impressively long PFS (59% free from PD or death at 18mo!!). Reasonable strategy from next Monday in TKI-naive patients.

Post attachmentPost attachmentPost attachmentPost attachment
ESMO Open avatar
ESMO Open@ESMO_Open·Aug 23

Safety & efficacy of sotorasib + panitumumab & FOLFIRI for previously treated KRAS G12C-mutated metastatic CRC in the CodeBreaK 101 ph Ib study in @ESMO_Open. 50% G3 or higher TRAEs (mainly skin tox & WBC decrease), ORR 56.5%, mPFS & mOS 8.3 & 17.9 months. esmoopen.com/article/S2059-7…

Post attachment
ESMO Open avatar
ESMO Open@ESMO_Open·Aug 23

HER2DX in early-stage HER2-positive BC: a review of clinical utility in @ESMO_Open. Genomic-clinical test with providing prognostic relapse risk score, pCR score, ERBB2 mRNA expression score. Potential support for individualized Tx discussion. esmoopen.com/article/S2059-7…

Post attachment
ESMO Open avatar
ESMO Open@ESMO_Open·Aug 3

MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma in @ESMO_Open. MYC-R is poor prognostic marker and refines the double-hit risk model, while gain/amp may be a high risk factor, esmoopen.com/article/S2059-7…

Post attachment
ESMO Open avatar
ESMO Open@ESMO_Open·Aug 3

Final analysis of the FeDeriCa ph III study: long-term efficacy, safety & PKs of the fixed-dose combination of pertuzumab & trastuzumab for s.c. injection, plus CT in HER2+ early BC in @ESMO_Open. Comparable long-term efficacy, no new safety signals. esmoopen.com/article/S2059-7…

Post attachment
ESMO Open avatar
ESMO Open@ESMO_Open·Jul 31

Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study in @ESMO_Open. Fusobacterium spp presence identifies CRC with aggressive biology, immunesuppression and reduced adjuvant CT benefit. esmoopen.com/article/S2059-7…

Post attachment
ESMO Open avatar
ESMO Open@ESMO_Open·Jul 31

Comparative efficacy of perioperative systemic therapies for MIBC: a network meta-analysis of randomized trials in @ESMO_Open. Improved OS with EV/GC + durva vs GC. Although indirect comparative estimates, EV ranks highest across OS, EFS, and pCR. esmoopen.com/article/S2059-7…

Post attachment